AMACR and prostate cancer: Nevertheless, PSA testing is still a contentious issue for it often leads to false results, overdiagnosis, and false therapy going along with high costs.[24] The identification of further biomarkers, e.g., PCA3, GSTP1, AMACR, or miRNAs, reveals the opportunity to improve prostate cancer detection.[25] Additionally, new biomarkers may enhance monitoring and give a more detailed view into cancer progress and development.